Effect of Vitamin D Supplementation on Oral Glucose Tolerance Among Obese Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Childhood obesity is a rapidly growing epidemic in the US and the world. Current estimates suggest that 30% of our nation's children are either overweight ot obese. Obesity is a major risk factor towards the development of insulin resistance, which, in turn is a major risk factor for the development of type 2 diabetes. Prior research has suggested that vitamin D therapy may be a safe, inexpensive, and effective method of reducing insulin resistance and a person's risk of developing diabetes.

The investigators' prior studies have shown that daily 4,000 IU vitamin D therapy is a safe and effective method of improving insulin resistance based on a calculation called the HOMA-IR.

The next step in identifying whether vitamin D truly improves insulin resistance is to use oral glucose tolerance testing (OGTT), which is a better real-life measure of insulin resistance compared to the previously used HOMA-IR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vitamin D to Improve Glucose Metabolism and Reduce Inflammation in Obese Adolescents

NCT00994396

Obesity Glucose Intolerance Inflammation

COMPLETED NA

Efficacy of Vitamin D Supplementation in Obese Children

NCT02956408

Obesity, Pediatric Obesity, Childhood Obesity, Morbid +1 more

COMPLETED NA

Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents

NCT00858247

Obesity

COMPLETED PHASE2

Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents

NCT02414529

Vitamin D Deficiency

COMPLETED NA

Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth

NCT02168660

Obesity Insulin Resistance Vitamin D Deficiency

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators intend to recruit 20 obese adolescent subjects from the PI's obesity clinic to participate in the study. Investigators expect 5 to drop out, therefore leaving 15 subjects to complete the study. Eligible and assenting subjects (with consent from a parent) will be admitting to the Pediatric Procedure Suite and MU Women's and Children's Hospital. They will have an IV placed in the arm by a nurse experienced with working with children. The subjects will have blood drawn from the IV checking for vitamin D level, insulin, glucose, and c-peptide level (another marker for insulin status). The subject will then be asked to drink a 75 gram glucose solution. Additional blood will be drawn from the IV site to check for glucose, insulin, and c-peptide levels at 30 minutes, 60 minutes, 90 minutes, and 120 minutes. A total of 30 mL (2 tablespoons) of blood will be drawn that day. The subject will have the IV removed and will be discharged to then take two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.

At a routine 3 months clinical visit, the subject will be tested for routine, standard of care, basic metabolic profile (BMP) with 4 ml of blood (less than 1 teaspoon) to assess for high calcium levels, a potential complication of vitamin D therapy. In the investigators' previous study of adolescents taking 4,000 IU vitamin D daily for six months, no subject developed a high calcium level.

At six months, the subject will return to the Pediatric procedure suite to have another OGTT and labs via IV as described above.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

4,000 IU Vitamin D3

two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.

Group Type EXPERIMENTAL

4,000 IU vitamin D3

Intervention Type DIETARY_SUPPLEMENT

two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

4,000 IU vitamin D3

two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Obese adolescent (BMI \>85th percentile for age)
* 9-19 years of age
* attending the ADOBE clinic at the University of Missouri
* 25OH vitamin D level within past 3 months

Exclusion Criteria

* use of vit D supplements other than standard multi-vitamin preparation (i.e., should not be receiving vit D \> 1000 IU/d)
* use of medications that interfere with vit D metabolism (e.g., anti-convulsive)
* history of hepatic or renal disorders, hypercalciuria, or hypercalcemia
* undergoing UV radiation as medical therapy
* pregnancy; cigarette smoking; current use of a tanning bed
* current type 2 diabetes
* any current antihyperglycemic medication use (e.g. metformin, insulin) less than one month prior to initial OGTT.

Minimum Eligible Age

9 Years

Maximum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes